Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19

Veru Inc VERU has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients.
Sabizabulin an oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties.
The 300-subject trial is evaluating daily oral doses of 9mg sabizabulin for up to 21 days versus placebo.
Subjects in the sabizabulin and placebo arms will also be allowed to receive standard of care.
The primary efficacy endpoint will be the proportion of patients that die on study up to Day 60.
Secondary endpoints will include the proportion of patients without respiratory failure, days in ICU, Clinical Improvement, days on mechanical ventilation, days in the hospital, and viral load.
Enrollment is targeted to be completed by year-end.
Price Action: VERU shares are down 1.50% at $7.90 on the last check Wednesday.
Related content: Benzinga's Full FDA Calendar